• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部癌症患者的纤维蛋白溶解-凝血系统。初步报告。

Fibrinolysis-coagulation system in patients with cancer of the head and neck. Preliminary report.

作者信息

Kosugi T, Takagi I, Ariga Y, Okada S, Morimitsu T, Mihara H

出版信息

Arch Otorhinolaryngol. 1982;236(3):211-5. doi: 10.1007/BF00454212.

DOI:10.1007/BF00454212
PMID:7159273
Abstract

Five parameters of blood coagulation and fibrinolysis, viz., levels of fibrinogen, fibrinolytic activity of euglobulin, fibrinogen and/or fibrin-degradation products (FDP), antiplasmin activity, and antithrombin activity, were measured in patients with cancer of the head and neck, and the results were compared with those of healthy adults. The fibrinogen content in cancer was significantly increased (p less than 0.001), the fibrinolytic activity of euglobulin significantly enhanced (p less than 0.001), the antiplasmin activity significantly reduced (p less than 0.05), the antithrombin activity significantly reduced (p less than 0.001), and the FDP level slightly increased, although the difference was not significant. The importance of the coagulation and fibrinolytic system in cancer of the head and neck is discussed.

摘要

对头颈部癌症患者测定了凝血和纤维蛋白溶解的五个参数,即纤维蛋白原水平、优球蛋白的纤维蛋白溶解活性、纤维蛋白原和/或纤维蛋白降解产物(FDP)、抗纤溶酶活性及抗凝血酶活性,并将结果与健康成年人的结果进行了比较。癌症患者的纤维蛋白原含量显著增加(p<0.001),优球蛋白的纤维蛋白溶解活性显著增强(p<0.001),抗纤溶酶活性显著降低(p<0.05),抗凝血酶活性显著降低(p<0.001),FDP水平略有升高,尽管差异不显著。本文讨论了凝血和纤维蛋白溶解系统在头颈部癌症中的重要性。

相似文献

1
Fibrinolysis-coagulation system in patients with cancer of the head and neck. Preliminary report.头颈部癌症患者的纤维蛋白溶解-凝血系统。初步报告。
Arch Otorhinolaryngol. 1982;236(3):211-5. doi: 10.1007/BF00454212.
2
[Thrombocyte function and problems of blood coagulation and fibrinolysis in head and neck cancer].[头颈部癌症中的血小板功能及血液凝固与纤维蛋白溶解问题]
HNO. 1984 Apr;32(4):177-9.
3
Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo.眩晕患者凝血-纤溶系统及血小板功能抑制剂
Auris Nasus Larynx. 1986;13 Suppl 1:S75-9. doi: 10.1016/s0385-8146(86)80038-4.
4
Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.体外膜肺氧合中凝血和纤维蛋白溶解激活标志物的年龄差异。
Pediatr Crit Care Med. 2014 Jun;15(5):e198-205. doi: 10.1097/PCC.0000000000000107.
5
Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment.接受保守治疗的慢性肾衰竭患者的凝血与纤溶功能
Thromb Res. 1991 Oct 1;64(1):81-90. doi: 10.1016/0049-3848(91)90207-d.
6
Activation of thrombosis and fibrinolysis following brain infarction.脑梗死后脑血栓形成与纤溶激活。
J Neurol Sci. 2000 Dec 1;181(1-2):82-8. doi: 10.1016/s0022-510x(00)00435-4.
7
Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.体外循环后纤溶与血小板功能和出血的关系。
Blood Coagul Fibrinolysis. 1994 Oct;5(5):679-85. doi: 10.1097/00001721-199410000-00002.
8
Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment.接受定期血液透析治疗患者的凝血-纤溶功能增强。
Nephron. 1991;58(2):201-4. doi: 10.1159/000186415.
9
Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia.子宫腺肌病导致的凝血和纤维蛋白溶解系统功能障碍是血栓形成和月经过多的一个可能原因。
Eur J Obstet Gynecol Reprod Biol. 2016 Sep;204:99-103. doi: 10.1016/j.ejogrb.2016.07.499. Epub 2016 Aug 3.
10
Basic Evaluation of the Newly Developed "Lias Auto P-FDP" Assay and the Influence of Plasmin-α2 Plasmin Inhibitor Complex Values on Discrepancy in the Comparison with "Lias Auto D-Dimer Neo" Assay.新开发的“Lias Auto P-FDP”检测方法的基本评估以及纤溶酶-α2纤溶酶抑制剂复合物值对与“Lias Auto D-Dimer Neo”检测方法比较时差异的影响。
Clin Lab. 2018 Apr 1;64(4):433-442. doi: 10.7754/Clin.Lab.2017.170902.

引用本文的文献

1
Platelet and Cancer-Cell Interactions Modulate Cancer-Associated Thrombosis Risk in Different Cancer Types.血小板与癌细胞的相互作用调节不同癌症类型中癌症相关血栓形成的风险。
Cancers (Basel). 2022 Jan 30;14(3):730. doi: 10.3390/cancers14030730.
2
Oral Squamous Cell Carcinoma Is Associated with a Low Thrombosis Risk Due to Storage Pool Deficiency in Platelets.口腔鳞状细胞癌与血小板储存池缺陷导致的低血栓形成风险相关。
Biomedicines. 2021 Feb 24;9(3):228. doi: 10.3390/biomedicines9030228.
3
Thrombosis Risk Associated with Head and Neck Cancer: A Review.

本文引用的文献

1
The fibrin plate method for estimating fibrinolytic activity.用于评估纤维蛋白溶解活性的纤维蛋白平板法。
Arch Biochem Biophys. 1952 Oct;40(2):346-51. doi: 10.1016/0003-9861(52)90121-5.
2
Malignancy and haemostasis.恶性肿瘤与止血
Br J Haematol. 1980 Feb;44(2):173-82. doi: 10.1111/j.1365-2141.1980.tb01199.x.
3
The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle.采用新型抗体包被乳胶颗粒检测纤维蛋白原 - 纤维蛋白降解产物。
头颈部癌症相关的血栓风险:综述
Int J Mol Sci. 2019 Jun 11;20(11):2838. doi: 10.3390/ijms20112838.
4
Identification of a plasminogen activator derived from nasopharyngeal carcinoma.源自鼻咽癌的纤溶酶原激活剂的鉴定。
Eur Arch Otorhinolaryngol. 1990;247(6):374-8. doi: 10.1007/BF00179011.
J Clin Pathol. 1972 Aug;25(8):680-2. doi: 10.1136/jcp.25.8.680.
4
Standard for human thrombin.人凝血酶标准品
Thromb Diath Haemorrh. 1975 Sep 30;34(1):3-18.
5
Problems in the assay of thrombin using synthetic peptides as substrates.使用合成肽作为底物测定凝血酶时存在的问题。
Thromb Res. 1977 Apr;10(4):549-56. doi: 10.1016/0049-3848(77)90210-9.
6
Unreliability of chromogenic substrates for assay of the clotting activity of thrombin.用于凝血酶凝血活性测定的显色底物的不可靠性。
Haemostasis. 1978;7(2-3):109-12. doi: 10.1159/000214246.
7
Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.
Haemostasis. 1978;7(2-3):138-45. doi: 10.1159/000214252.
8
Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.利用纤溶酶特异性三肽底物测定人血液中一种新型快速纤溶酶抑制剂。
Scand J Clin Lab Invest. 1977 Sep;37(5):403-9.